- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Radioactive Nanoparticles to Specifically Target Neuroblastomas
Developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, the technology uses tiny radioactive liposomes, inserted directly into a tumor with a thin catheter. The first-in-human trial was just initiated.
David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor.
The technology, developed at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, uses tiny radioactive liposomes, or fat particles, only 100 nanometers across, inserted by the thinnest of catheters directly into a tumor. There they remain, radiating only a tiny distance, affecting only the tumor.
Andrew Brenner, MD, PhD, a neuro-oncologist, is leading the clinical trial at the CTRC, and expects to start the second patient on the study within a month.
At his first follow-up appointment Monday, Williams reported feeling great, and said he did not experience the side effects that one normally does after conventional radiation therapy. That technology must send its beams through healthy tissue to reach the tumor, and so must be limited in the amount of radiation it delivers.
Read the complete press release at EurekAlert!:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
